Using a closed-system protective device to reduce personnel exposure to antineoplastic agents

American Journal of Health-System Pharmacy

Volumn 60, Issue 22, 2003, Pages 2314-2320

  Wick, Catherine ^a   Slawson, Matthew H ^b   Jorgenson, James A ^b   Tyler, Linda S ^b  

^a UNIVERSITY OF UTAH HOSPITAL   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Antineoplastic agents; Contamination; Cyclophosphamide; Equipment; Health professions; Ifosfamide; Injections; Safety; Toxicity, environmental

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; IFOSFAMIDE; ALKYLATING AGENT;

ARTICLE; CONTROLLED STUDY; DRUG CONTAMINATION; DRUG DETERMINATION; DRUG EXPOSURE; DRUG INFUSION; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MEDICAL STAFF; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; PROTECTIVE EQUIPMENT; URINALYSIS; ENVIRONMENTAL MONITORING; HOSPITAL PERSONNEL; METHODOLOGY; PUBLIC HEALTH; URINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; ENVIRONMENTAL MONITORING; HUMANS; IFOSFAMIDE; OCCUPATIONAL EXPOSURE; PERSONNEL, HOSPITAL; PROTECTIVE DEVICES; PUBLIC HEALTH;

EID: 1542750054     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.22.2314     Document Type: Article

References (34)

1. Crudi CB, Stephens BL, Maier P. Possible occupational hazards associated with the preparation/administration of antineoplastic agents. NITA. 1982; 4:264-5.
2. Falck K, Grohn P, Sorsa M et al. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet. 1979; 1:1250-1.
3. Kleinberg ML, Quinn MJ. Airborne drug levels in a laminar-flow hood. Am J Hosp Pharm. 1981; 38:1301-3.
4. Hirst M, Tse S, Mills DG et al. Caution on handling antineoplastic drugs. N Engl J Med. 1983; 309:188-9.
5. Anderson RW, Puckett WH Jr, Dana WJ et al. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm. 1982; 39:1881-7.
6. Nguyen TV, Theiss JC, Matney TS. Exposure of pharmacy personnel to mutagenic antineoplastic drugs. Cancer Res. 1982; 42:4792-6.
7. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic drugs in hospitals. Am J Hosp Pharm. 1985; 42:131-7.
8. American Medical Association Council on Scientific Affairs. Guidelines for handling parenteral antineoplastics. JAMA 1985; 253:1590-2.
9. Recommendations for handling cytotoxic agents. Providence, RI: National Study Commission on Cytotoxic Exposure; 1987 Sep.
10. Cancer chemotherapy guidelines: recommendations for nursing practice in the acute care setting. Pittsburgh, PA: Oncology Nursing Society, 1982.
11. U.S. Department of Labor guidelines for cytotoxic drugs. Washington, DC: Office of Occupational Medicine, U.S. Occupational Health and Safety Administration, 1986; publication no. 8-1.1.
12. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hasp Pharm. 1990; 47:1033-49.
13. ONS Clinical Practice Committee. Cancer chemotherapy guidelines and recommendations for practice. Pittsburgh, PA: Oncology Nursing Society; 1999:32-41.
14. Best practices for health-system pharmacy. 2002-2003 edition. Bethesda, MD: American Society of Health-System Pharmacists; 2003.
15. Baker ES, Connor TH. Monitoring occupational exposure to cancer chemotherapy drugs. Am J Health-Syst Pharm. 1996; 53:2713-23.
16. Sessink PJ, Anzion RB, Van den Broek PH et al. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci. 1992; 14:16-22.
17. McDevitt JJ, Lees PS, McDiarmid MA. Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med. 1993; 35:57-60.
18. Ensslin AS, Pethran A, Schierl R et al. Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs. Int Arch Occup Environ Health. 1994; 65:339-42.
19. Ensslin AS, Stoll Y, Pethran A et al. Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med. 1994; 51:229-33.
20. Sessink PJ, Boer KA, Scheefhals AP et al. Occupational exposure to antineoplastic agents at several departments in a hospital: environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health. 1992; 64:105-12.
21. Labuhn K, Valanis B, Schoeny R et al. Nurses' and pharmacists' exposure to antineoplastic drugs: findings from industrial hygiene scans and urine mutagenicity tests. Cancer Nurs. 1998; 21:79-89.
22. Connor TH, Anderson RW, Sessink PJ et al. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health-Syst Pharm. 1999; 56:1427-32.
23. Valanis B, Vollmer WM, Steele P. Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med. 1999; 41:632-8.
24. Kiffmeyer TK, Kube C, Opiolka S et al. Vapour pressures, evaporation behavior and airborne concentrations of hazardous drugs: implications for occupational safety. Pharm J. 2002; 268:331-7.
25. Connor TH, Shults M, Fraser MP. Determination of the vaporization of solutions of mutagenic antineoplastic agents at 23 and 37°C using a desiccator technique. Mutat Res. 2000; 470:85-92.
26. Gebhart F. Watch out! Secondhand chemo alert due from NIOSH. Drug Top. 2002; 10:HSEI.
27. Connor TH, Anderson RW, Sessink PJ et al. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health-Syst Pharm. 2002; 59:68-72.
28. Vandenbrouke J, Robays H. How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Pract. 2001; 6:146-52.
29. Sessink PJ, Rolf ME, Ryden NS. Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm. 1999; 34: 1311-7.
30. Sottani C, Turd R, Perbellini L et al. Liquid-liquid extraction procedure for trace determination of cyclophosphamide in human urine by high-performance liquid chromatography tandem mass spectrometry. Rapid Commun Mass Spectrom. 1998; 12:1063-8.
31. Spivey S, Connor TH. Determining sources of workplace contamination with antineoplastic drugs and comparing conventional i.V. drug preparation with a closed system. Hosp Pharm. 2003; 38:135-9.
32. Nygren O, Gustavsson B, Strom L et al. Exposure to anti-cancer drugs during preparation and administration. Investigations of an open and a closed system. J Environ Monit. 2002; 4:739-42.
33. Pethran A, Schierl R, Hanff K et al. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations. Int Arch Occup Environ Health. 2003; 76:5-10.
34. Schreiber C, Radon K, Pethran A. Uptake of antineoplastic agents in pharmacy personnel. Part II: study of work-related risk factors. Int Arch Occup Environ Health. 2003; 76:11-6.